免疫疗法
内科学
危险系数
医学
生物标志物
临床试验
无进展生存期
胃肠病学
肿瘤科
肿瘤进展
循环肿瘤DNA
癌症
置信区间
总体生存率
生物
遗传学
作者
Enrique Sanz‐García,Sofia Genta,Xiaoxi Chen,Qiuxiang Ou,Daniel Vilarim Araújo,Albiruni R. Abdul Razak,Aaron R. Hansen,Anna Spreafico,Hua Bao,Xue Wu,Lillian L. Siu,Philippe L. Bédard
摘要
A decrease in ctDNA within 4 weeks of treatment was associated with treatment outcomes in patients in early phase IO trials. Tumor-naïve ctDNA assays may be useful for identifying early treatment benefits in phase I/II IO trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
大力的冬萱
cdercder
Copyright
liuzhuohao
行走的荷尔蒙
ale
Avalonx
Nole
arniu2008
认真的不评
OK
sanvva
Oracle
yjh123
Astraeus
昏睡的蟠桃
无情的聪健
初景
科研狗
皖公网安备34019202002308
